Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 200 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing scientific conference presentations and clinical trial results, not an earnings release, management change, capital transaction, or formal regulatory report. It does not fit any specific financial filing category, so it falls into the general regulatory announcements fallback category.
2026-04-27 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a corporate press release announcing the appointment of two leading oncologists to its Scientific Advisory Board. There are no financial results, report attachments, or regulatory form submissions. It specifically relates to changes in the company's advisory/management structure. This matches the definition of a Board/Management Information announcement.
2026-04-16 English
News release - English.pdf
Regulatory Filings Classification · 92% confidence The document is a corporate press release announcing clinical study histology analysis results and forward-looking statements. It is not an annual or interim financial report, earnings release, management discussion, regulatory submission of an official filing, or investor presentation. It does not fit any specific category other than a general company announcement. Therefore, it falls into the fallback category “Regulatory Filings (RNS)” used for miscellaneous corporate disclosures and press releases.
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release describing the publication of a preclinical study in a scientific journal, with forward-looking statements and no financial figures, meeting results, or regulatory filings. It is not an earnings release, annual/interim report, management change, or dividend notice, nor does it announce any corporate meeting materials or formal report attachments. It therefore falls into the fallback category for miscellaneous regulatory announcements.
2026-04-07 English
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the publication of a peer‐reviewed preclinical study in a scientific journal. It does not present financial results, regulatory change notices, share transactions, dividend or capital raising details, or any AGM/EGM materials. It is also not an investor presentation, MD&A, earnings release, or statutory report. Therefore, it falls into the miscellaneous fallback category for regulatory or newswire filings.
2026-04-07 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled “Management Discussion and Analysis” and refers to review of performance for the three-month period ended January 31, 2026, prepared under IFRS. It contains forward‐looking statements, risk factors, business overview, strategy and R&D discussion, all hallmarks of an MD&A section. This is not a short announcement but a full MD&A, fitting the Management Reports (MDA) category rather than the complete interim report (IR) or an announcement of publication (RPA).
2026-03-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.